Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation of nivolumab and pembrolizumab pharmacokinetic and pharmacodynamic assays
NL-OMON47401Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nivolumab and pembrolizumab in Nonhematologic neoplasms and metastasis (2 arms), sponsored by Netherlands Cancer Institute. Started Jun 2017; status: recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasmsmetastasis
Beyond the preview
Go deeper on NL-OMON47401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47401.